Cytovia Therapeutics
Cytovia Therapeutics is an AI-powered discovery engine focused on developing advanced immune therapeutics for cancer and immunology. They specialize in harnessing the innate immune system with two core platforms: Flex-NK™ bispecific antibodies designed to engage natural killer (NK) cells, and iPSC-derived, TALEN® gene-edited NK cells (iNK and CAR-iNK) for improved function and tumor targeting. Their R&D center in Massachusetts and GMP manufacturing in Puerto Rico, supported by key scientific partnerships, aim to accelerate the transformation of cancer therapy. Cytovia has also formed a joint venture, CytoLynx Therapeutics, for activities in Greater China. The company is developing treatments for solid tumors and hematological malignancies, with clinical studies expected to initiate.
Cytovia Therapeutics
Cytovia Therapeutics is an AI-powered discovery engine focused on developing advanced immune therapeutics for cancer and immunology. They specialize in harnessing the innate immune system with two core platforms: Flex-NK™ bispecific antibodies designed to engage natural killer (NK) cells, and iPSC-derived, TALEN® gene-edited NK cells (iNK and CAR-iNK) for improved function and tumor targeting. Their R&D center in Massachusetts and GMP manufacturing in Puerto Rico, supported by key scientific partnerships, aim to accelerate the transformation of cancer therapy. Cytovia has also formed a joint venture, CytoLynx Therapeutics, for activities in Greater China. The company is developing treatments for solid tumors and hematological malignancies, with clinical studies expected to initiate.